REMAP-CAP (Randomised, Embedded, Multifactorial, Adaptive Platform for Community-Acquired Pneumonia) is a large international research project. It helps find the best treatments for patients with severe chest infections who are critically ill and need care in an intensive care unit (ICU).
This research project is designed to look at several treatments at the same time instead of testing one treatment at a time, like traditional trials. The goal is to learn faster which treatments work best for different types of patients.Â
Patients in this research project do not necessarily receive all treatments. Each patient is only offered the treatments that are available at their hospital, approved by their treating doctor, and suitable for their specific health condition. Once offered, the patient or their relative is asked to give consent for those treatments. No treatment is given without permission.
Some treatments that are currently being tested as part of the research project include:
Treatments that have been tested as part of the research project in the past:
These are all widely used, safe treatments in standard medical practice. REMAP-CAP is studying how to use them most effectively and in which patients they work best.
REMAP-CAP is designed to find out which treatments help patients the most. The study can adjust in real time based on what is working well, while stopping less effective options sooner. Thanks to its special design, REMAP-CAP can test several treatments more quickly and effectively than traditional studies, but always in a careful, controlled, and safe way.Â
Based on previous research and clinical experience, researchers hope that:
Each treatment is carefully chosen by experts to find out which patients benefit most from each treatment, while ensuring patient safety throughout the study.Â
Name: Prof Madiha Hashmi
Designation: Principal Investigator
Email: [email protected]
Contact No: 021 35862937, Ext. 4460